⌘K
Loading ticker…
As of 2026-08-24, ALX Oncology Holdings Inc. Common Stock (ALXO) has a 3-month relative strength percentile of 49 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 56. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.6%, relative volume 0.25×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ALXO is in a stage 2 uptrend, week 1. Currently in a 128-day base; basing ADR 8.0% (broad 10.1%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 1.4% / 11.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ALXO is held by 2 ETFs as of May 2026. Top owner: VHT at 0.00% weight, $185K notional.
Held by 5 ETFs · $8M across latest filings · largest weight 0.00% (VXF).
Top 2 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.00% | $185K | — |
| AVSC | 0.00% | $15K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALXO Jan avg: 5.18% median: -7.90% win: 25% σ: 33.07% n: 4 2022-04-12 → 2026-07-31 | ALXO Feb avg: -7.60% median: -11.43% win: 50% σ: 23.54% n: 4 2022-04-12 → 2026-07-31 | ALXO Mar avg: -26.01% median: -27.86% win: 0% σ: 16.13% n: 4 2022-04-12 → 2026-07-31 | ALXO Apr avg: 6.33% median: -13.32% win: 40% σ: 33.68% n: 5 2022-04-12 → 2026-07-31 | ALXO May avg: -12.71% median: -10.09% win: 40% σ: 25.45% n: 5 2022-04-12 → 2026-07-31 | ALXO Jun avg: -6.15% median: 5.48% win: 60% σ: 23.25% n: 5 2022-04-12 → 2026-07-31 | ALXO Jul avg: 2.21% median: -6.28% win: 40% σ: 25.06% n: 5 2022-04-12 → 2026-07-31 | ALXO Aug avg: 14.63% median: 2.01% win: 50% σ: 71.13% n: 4 2022-04-12 → 2026-07-31 (current) | ALXO Sep avg: 5.29% median: -4.44% win: 50% σ: 38.26% n: 4 2022-04-12 → 2026-07-31 | ALXO Oct avg: 9.89% median: 5.50% win: 50% σ: 34.35% n: 4 2022-04-12 → 2026-07-31 | ALXO Nov avg: -1.80% median: -2.54% win: 50% σ: 9.55% n: 4 2022-04-12 → 2026-07-31 | ALXO Dec avg: 21.69% median: 7.18% win: 75% σ: 47.18% n: 4 2022-04-12 → 2026-07-31 |